Human papillomaviruses (HPVs) are a major cause of anogenital and head and neck neoplasms and malignancies.? Unfortunately, no specific antiviral therapies for HPV infection or HPV-induced malignancies have been identified.? This U19 proposal is submitted as project by Alexander in a consortium proposal entitled siRNA Microbicides. The goal of this? research consortium is to develop native and chemically modified siRNAs as effective means for blocking? transmission of HIV, HSV2 and HPV. In project by Alexander, we hypothesize that chemically modified single-stranded? boranophosphate-backbone short interfering RNAs (siRNAs) are superior to native siRNAs for potent and durable? gene silencing, and that anti-HPV E6/E7 single-stranded boranophosphate-backbone siRNAs (ssBP-siRNAs) can be? used to effectively block HPV viral replication and proliferation of HPV-transformed cells. By combining chemical? modifications shown individually to increase siRNA silencing potency and duration, we will create ssBP-siRNAs,? designed for topical delivery, that block episome replication in HPV-infected cells and induce irreversible growth? arrest in HPV16-transformed cells. Anti-HPV16 ssBP-siRNAs identified by us will be tested in project 3 using novel? cell culture and transgenic mouse models of HPV infection.? Project 3 will also supply optimized ssBP-siRNAs to projects by Ramratnam and Herold to allow comparison of ssBP-siRNAs with? conventional siRNAs for targeting expression of macaque CCR5, murine focal adhesion kinase, and murine nectin-1.? To allow immediate work optimizing ssBP-siRNA delivery to vaginal mucosa, we will supply existing highly active? ssBP-siRNAs to Core B (Formulations). The vaginal mucosal uptake and activity of formulated ssBP-siRNAs will be? assessed quantitatively in project 3.? At the conclusion of this study, we will have developed anti-HPV16 E6/E7 ssBP-siRNAs as effective topical? microbicides for prevention of HPV infection and HPV-induced malignancies. We will also have created high potency? ssBP-siRNAs active against other consortium targets, and forwarded these ssBP-siRNAs for microbicidal testing in? laboratory models of viral infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI070202-01
Application #
7132116
Study Section
Special Emphasis Panel (ZRG1-AARR-A (40))
Project Start
2006-07-01
Project End
2010-08-31
Budget Start
2006-07-01
Budget End
2007-08-31
Support Year
1
Fiscal Year
2006
Total Cost
$215,908
Indirect Cost
Name
Rhode Island Hospital
Department
Type
DUNS #
075710996
City
Providence
State
RI
Country
United States
Zip Code
02903
Song Gao, Jin; Zhang, Yingjie; Li, Ming et al. (2010) Atypical transcription of microRNA gene fragments. Nucleic Acids Res 38:2775-87
Cheshenko, Natalia; Trepanier, Janie B; Segarra, Theodore J et al. (2010) HSV usurps eukaryotic initiation factor 3 subunit M for viral protein translation: novel prevention target. PLoS One 5:e11829
LaFrance Jr, W C; Keitner, G I; Papandonatos, G D et al. (2010) Pilot pharmacologic randomized controlled trial for psychogenic nonepileptic seizures. Neurology 75:1166-73
Huang, Hao-Shun; Buck, Christopher B; Lambert, Paul F (2010) Inhibition of gamma secretase blocks HPV infection. Virology 407:391-6
Wilson, Sarah S; Fakioglu, Esra; Herold, Betsy C (2009) Novel approaches in fighting herpes simplex virus infections. Expert Rev Anti Infect Ther 7:559-68
Cheshenko, Natalia; Liu, Wen; Satlin, Lisa M et al. (2007) Multiple receptor interactions trigger release of membrane and intracellular calcium stores critical for herpes simplex virus entry. Mol Biol Cell 18:3119-30